(Source: Viralytics Limited) Viralytics Limited (ASX: VLA, OTC: VRACY)is pleased to announce initial results from the Phase 1 CAVATAK Bladder Trial (CANON) which will be released at the 9th International Conference on Oncolytic Virus Therapeutics in Boston 13-16 June. Other presentations on CAVATAK at the conference will highlight its potential in a range of cancers. The company announcement on the presentations can be found on our website here. Further details will be available following the conference....
↧